PMID- 36581507
OWN - NLM
STAT- MEDLINE
DCOM- 20230303
LR  - 20240302
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 84
IP  - 3
DP  - 2023 Mar
TI  - Virtual crossmatch for deceased donor kidney transplantation in the United 
      States: A survey of histocompatibility lab directors and transplant surgeons.
PG  - 214-223
LID - S0198-8859(22)00250-6 [pii]
LID - 10.1016/j.humimm.2022.12.001 [doi]
AB  - Virtual crossmatch (VXM) is used as an alternative to or in conjunction with a 
      cell-based physical crossmatch (PXM) for assessing HLA (human leukocyte antigen) 
      compatibility prior to deceased donor kidney transplantation (DDKT). Data on 
      practice patterns and perceptions regarding VXM use in the US are limited. We 
      performed a survey of US HLA directors and transplant surgeons regarding HLA 
      testing and crossmatch strategies. 53 (56 %) HLA directors and 68 surgeons 
      (representing  approximately  23 % of US transplant centers) completed the survey. Both groups 
      agreed that VXM could reduce cold ischemia time (CIT), costs and improve 
      allocation efficiency. VXM use increased following the 2021 kidney allocation 
      change. Reducing CIT was the primary reason for favoring VXM over PXM. Preference 
      for VXM reduced as candidates' panel reactive antibodies increased. Regulations, 
      program policies and limitations of HLA technology were cited as important 
      reasons for preferring PXM over VXM. Surgeons reported similar perceptions, but 
      findings are limited by the low response rate. Finally, half the labs reported 
      lacking specific protocols for VXM use. In conclusion, improved HLA technology 
      and protocols along with changes to institutional procedures and policy 
      regulations are needed for safer expansion of VXM in DDKT.
CI  - Copyright (c) 2022 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Puttarajappa, Chethan M
AU  - Puttarajappa CM
AD  - Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, 
      Pittsburgh, USA. Electronic address: puttarajappacm@upmc.edu.
FAU - Tevar, Amit D
AU  - Tevar AD
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, USA.
FAU - Hoffman, William
AU  - Hoffman W
AD  - Transplant Nephrology, UPMC Pinnacle, Harrisburg, PA, USA.
FAU - Degenholtz, Howard
AU  - Degenholtz H
AD  - Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, 
      USA.
FAU - Schinstock, Carrie A
AU  - Schinstock CA
AD  - Division of Nephrology, Mayo Clinic, Rochester, USA.
FAU - Gunabushanam, Vikraman
AU  - Gunabushanam V
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, USA.
FAU - Zeevi, Adriana
AU  - Zeevi A
AD  - Department of Pathology, University of Pittsburgh, Pittsburgh, USA.
FAU - Xu, Qingyong
AU  - Xu Q
AD  - Department of Pathology, University of Pittsburgh, Pittsburgh, USA.
FAU - Hariharan, Sundaram
AU  - Hariharan S
AD  - Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, 
      Pittsburgh, USA.
LA  - eng
GR  - K08 DK119576/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20221227
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Humans
MH  - United States
MH  - *Kidney Transplantation/methods
MH  - Blood Grouping and Crossmatching
MH  - Histocompatibility Testing/methods
MH  - Kidney
MH  - HLA Antigens
MH  - Histocompatibility
MH  - Graft Rejection
PMC - PMC9991979
MID - NIHMS1861217
OTO - NOTNLM
OT  - Deceased donor
OT  - Histocompatibility
OT  - Kidney transplantation
OT  - Survey
OT  - Virtual crossmatch
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/12/30 06:00
MHDA- 2023/03/04 06:00
PMCR- 2024/03/01
CRDT- 2022/12/29 21:54
PHST- 2022/09/02 00:00 [received]
PHST- 2022/11/22 00:00 [revised]
PHST- 2022/12/20 00:00 [accepted]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2023/03/04 06:00 [medline]
PHST- 2022/12/29 21:54 [entrez]
PHST- 2024/03/01 00:00 [pmc-release]
AID - S0198-8859(22)00250-6 [pii]
AID - 10.1016/j.humimm.2022.12.001 [doi]
PST - ppublish
SO  - Hum Immunol. 2023 Mar;84(3):214-223. doi: 10.1016/j.humimm.2022.12.001. Epub 2022 
      Dec 27.